Results 21 to 30 of about 21,216 (279)

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

Clinical Infectious Diseases, 2010
Stephen J Gange
exaly   +3 more sources

Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study

Acta Médica Portuguesa, 2022
Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão, Kamal Mansinho, Fernando Maltez, Nuno Marques, Alexandre Carvalho, Rosário Pazos, Alexandra Zagalo, Josefina Mendez, Isabel Neves, Joaquim Oliveira, Patrícia Pacheco, Ricardo Correia de Abreu, Ana Cláudia Miranda, Paula Camacho, Laura Paixão, Joana Almeida   +15 more
doaj   +1 more source

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

Journal of Antimicrobial Chemotherapy, 2021
Background To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1.
C. Herrera, J. Lwanga, M. Lee, S. Mantori, Alieu Amara, L. Else, S. D. Penchala, D. Egan, E. Challenger, L. Dickinson, M. Boffito, R. Shattock, S. Khoo, J. Fox   +13 more
semanticscholar   +1 more source

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. [PDF]

, 2012
BackgroundLimited knowledge exists on early HIV events that may inform preventive and therapeutic strategies. This study aims to characterize the earliest immunologic and virologic HIV events following infection and investigates the usage of a novel ...
Ananworanich, Jintanat, Chomchey, Nitiya, Chomont, Nicolas, de Souza, Mark, Dewar, Robin, Kim, Jerome H, Maldarelli, Frank, Marovich, Mary, Michael, Nelson, Paris, Robert, Peel, Sheila, Phanuphak, Nittaya, Phanuphak, Praphan, Pinyakorn, Suteeraporn, Rerknimitr, Rungsun, Rutvisuttinunt, Wiriya, RV254/SEARCH 010 Study Group, Schuetz, Alexandra, Sekaly, Rafick, Sereti, Irini, Trichavaroj, Rapee, Valcour, Victor, van Griensven, Frits, Vandergeeten, Claire   +23 more
core   +8 more sources

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. [PDF]

PLoS ONE, 2016
BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods.
Lawrence Soon-U Lee, Kok-Yong Seng, Ling-Zhi Wang, Wei-Peng Yong, Kim-Hor Hee, Thomas I Soh, Andrea Wong, Pei F Cheong, Richie Soong, Nur S Sapari, Ross Soo, Lu Fan, Soo-Chin Lee, Boon C Goh   +13 more
doaj   +1 more source

Eficacia y seguridad en condiciones clínicas reales del raltegravir en un hospital de referencia del seguro social peruano

Enfermería Global, 2021
Introducción: El Rategravir pertenece a los inhibidores de integrasas, quedando demostrado y aprobado por diversos ensayos clínicos como un potente antirretroviral seguro y eficaz para el tratamiento de pacientes infectados con el virus de ...
Elias Contreras-Calero, Marcos Saavedra-Velasco, Fernando Mendo-Urbina , Carlos Muñoz-Medina, J. Antonio Grandez-Urbina, Rafael Pichardo-Rodriguez   +5 more
doaj   +1 more source

Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc

AIDS (London), 2021
Supplemental Digital Content is available in the text Objective: To evaluate the effect on anthropometric, metabolic and adipose tissue parameters of switching ART-controlled persons living with HIV (PLWH) from a protease inhibitor regimen to raltegravir/
J. Bastard, V. Pelloux, R. Alili, S. Fellahi, J. Aron‐Wisnewsky, Emilie Capel, B. Fève, L. Assoumou, Edi Prifti, C. Katlama, K. Clément, J. Capeau   +11 more
semanticscholar   +1 more source

Raltegravir in treatment naïve patients

European Journal of Medical Research, 2009
Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj   +1 more source

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen : a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from antiretroviral therapy-suppressed human immunodeficiency virus-infected individuals [PDF]

, 2018
Background: Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted ...
Blanco, Julià, Crespo, Manel, De Clercq, Laura, Gálvez, Cristina, Jimenez, Montse, Martinez-Picado, Javier, Moron-Lopez, Sara, Navarro, Jordi, Puertas, Maria C, Ribas, Bibiana Planas, Rutsaert, Sofie, Salgado, Maria, Torrella, Ariadna, Universitat Autònoma de Barcelona, Urrea, Víctor, Vandekerckhove, Linos   +15 more
core   +3 more sources

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source